Nasdaq GlobeNewswire

Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)

Del

WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from a recent pre-clinical study that provide evidence of  the effect of roluperidone (MIN-101) on BDNF. This neurotrophin, which is the most widely distributed member of this class of proteins in the brain, has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning, and memory.1  Its involvement in schizophrenia has also been described.2

Data from this  study are being presented today at the Medicxi Forum in Venice, Italy showing that after three days of administration, roluperidone has been observed to significantly increase the release of BDNF in cultured brain hippocampal neurons in a dose dependent manner. The level of BDNF release following the administration of roluperidone increased by approximately 20 percent, comparable to the effect shown by pridopidine, the reference molecule used in the study.  Pridopidine is currently under development for Huntington disease.3 

Dysregulation of BDNF has been described in the pathophysiology of schizophrenia and several other neuro-psychiatric disorders. Therefore, in addition to the known neurotransmitter pathways targeted by roluperidone, particularly the serotoninergic 5-HT2A and the sigma2 pathways, the effect of roluperidone on BDNF suggests that this investigational compound may have the potential for disease modification and improved neuroplasticity.

“These findings, along with the clinical results seen during the phase 2b study, suggest the potential of roluperidone to change the overall course of schizophrenia,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.  “In addition, the BDNF findings are paving the way to explore roluperidone’s therapeutic potential beyond schizophrenia.”

BDNF is a member of a family of proteins called neurotrophins that play an important role in the formation and function of neural connections.  An emerging body of evidence has pointed to a link between BDNF and CNS disorders.  Epigenetic changes in the BDNF gene have been shown to be related to the pathophysiology of schizophrenia, and the reduced expression of BDNF has been identified in the frontal cortex and hippocampus of the brain in patients with schizophrenia.4

Researchers believe that lower than normal levels of BDNF may affect the pathogenesis of schizophrenia by contributing to altered brain development and abnormalities in neuroplasticity and synaptic function.  These disturbances may explain certain morphological and neurochemical characteristics in the brains of patients with schizophrenia.5

Furthermore, a functional polymorphism in the BDNF gene has been observed to interact with environmental factors in the development of psychoses including schizophrenia and bipolar disorders.6  Additional studies have found an association between higher levels of BDNF and improved cognitive function in schizophrenic patients and improved neuropsychological function.7 

About Roluperidone

Roluperidone is a drug candidate with equipotent affinities for 5‑hydroxytryptamine-2A (5-HT2A) and sigma2 and at lower affinity levels, α1-adrenergic receptors. Roluperidone exhibits no affinity for dopaminergic, muscarinic, cholinergic and histaminergic receptors.  Roluperidone has no direct dopaminergic post-synaptic blocking effects, known to be involved in some side effects like extrapyramidal symptoms, sedation, prolactin increases and weight gain.

A pivotal Phase 3 clinical trial is ongoing with roluperidone as monotherapy for negative symptoms in patients diagnosed with schizophrenia.  Approximately 500 patients are expected to be enrolled at approximately 60 clinical sites in the U.S. and Europe.  Top-line results from the 12-week double blind phase of this trial are expected in the first half of 2019.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

_____________________
1 BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning and memory, R. Nieto et al, Frontiers in Psychiatry, June 2013, Volume 4 Article 45, https://doi.org/10.3389/fpsyt.2013.00045

2 Childhood trauma interacted with BDNF Val66Met influence schizophrenic symptoms, Xiao-jiao Bi et al, Medicine, http://dx.doi.org/10.1097/MD.0000000000010160

3 Pridopidine activates neuroprotective pathways impaired in Huntington Disease, M. Geva et al, Human Molecular Genetics, 2016, Volume 25 Number 18, doi:10.1093/hmg/ddw238 

4 Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampi of Chronic Restraint Stress Rats, Mi Kyoung Seo et al, https://doi.org/10.1155/2018/2682037

5 BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning and memory, R. Nieto et al, Frontiers in Psychiatry, June 2013, Volume 4 Article 45

6 Childhood trauma interacted with BDNF Val66Met influence schizophrenic symptoms, Xiao-jiao Bi et al, Medicine, http://dx.doi.org/10.1097/MD.0000000000010160

7 BDNF (brain-derived neurotrophic factor) serum levels in schizophrenic patients with cognitive deficits, N. Utami et al, doi:10.1088/1755-1315/125/1/012181

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CP Kelco Announces Plans to Invest in Specialty Biogums Capabilities and Capacity Expansion19.11.2018 14:15Pressemelding

ATLANTA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In response to the strong global demand for specialty Biogums products, CP Kelco announced today its plans to invest in building capabilities and expanding production capacity. As a leading global producer and innovator of hydrocolloid solutions, CP Kelco is reinforcing its commitment to three Biogums product lines – gellan gum, specialty xanthan gum and diutan gum – through these key operational initiatives: Adding gellan gum production capabilities in the company’s Wulian, China facility to support growth in the Asia Pacific region; Expanding the overall capacity of the Wulian, China facility to support growth across all three specialty Biogums product lines; and Expanding the recently added gellan gum production capacity in the company’s Okmulgee, Oklahoma, USA facility. In addition to the planned investments in new production capabilities and capacity, CP Kelco is equally committed to ensuring its Biogums products meet the high standards o

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan19.11.2018 14:00Pressemelding

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan. Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML). This submission complements Invivoscribe’s prior

Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers19.11.2018 14:00Pressemelding

Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals Tested formulation is used in ongoing Phase 3 trial Data to be reviewed at Minerva’s roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the results from a prospective, double-blind, placebo-controlled, randomized single-escalating dose study in healthy subjects to evaluate the investigational drug roluperidone as monotherapy administered at nine ascending doses (16, 32, 64, 96, 128, 160, 19

Clutch Ranks SoftServe Among the Top Data Analytics Companies in Ukraine19.11.2018 13:00Pressemelding

AUSTIN, Texas, Nov. 19, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has been named a top data analytics consulting company in Ukraine for its high-quality service in technology transformation consulting by Clutch, a leading B2B research, ratings, and reviews company based in Washington D.C. SoftServe ranked ninth out of more than 140 firms in the data analytics category. Clutch determines its industry leader rankings by using a methodology that evaluates companies based on industry expertise and the ability to deliver. Additional criteria includes services offered, types of clients, case studies, brand reputation, and visibility within the target market. “As part of Clutch’s service, we provide business to business firms the opportunity to evaluate companies and their competitors so that they can find the best partner to meet their needs,” said Jackie Faselt, Business Analyst at Clutch. “SoftServe’s technical expertise and positi

GridGain Experts Showcase the Power of In-Memory Computing at Multiple Industry Events19.11.2018 09:00Pressemelding

FOSTER CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Experts from GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, is organizing or taking part in multiple webinars, conferences and meetups during November and December to share the latest information and developments related to in-memory computing technology and business trends. “The performance challenges facing companies as they undertake digital transformation are vast, and for many companies an in-memory computing platform is the only cost-effective, easy-to-deploy technology capable of delivering the speed and scalability necessary to overcome many of those challenges,” said Terry Erisman, vice president of marketing at GridGain Systems. “Our experts travel the world to share practical advice on how to leverage the power of in-memory computing.” Conferences AWS Re:Invent 2018 – November 26, 2018 – GridGain CTO and Co-Founder Nikita Ivanov will speak on the topic of “In-Memor

Benchmark Assays 5.90 Metres at 12.62g/t AuEq From 2015 Drill-Hole That Also Provided 385.5 AuEq From Historical Assay19.11.2018 09:00Pressemelding

EDMONTON, Alberta, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Benchmark Metals Inc. (the “Company” or “Benchmark”) (TSX-V: BNCH) (OTCQB: CYRTF) (WKN: A2JM2X) - is pleased to announce drill-hole assays from the infill and shoulder sampling program of historical drill-core at the Lawyers Gold & Silver Project, located in the Golden Triangle region of British Columbia, Canada. Selected results from new and combined historical intersections include 5.9m at 12.62g/t AuEq (hole CC15-15), 63.75m at 1.59g/t AuEq (hole DR15-05), and 1.68m at 10.94g/t AuEq (hole DR15-01)*. CEO John Williamson commented, “Drill-hole assay results from selected historical holes continue to indicate that much of the Gold-Silver Lawyers project contains significant mineralization at surface and at shallow depths. Results from the Cliff Creek Zone and Dukes Ridge Zone are providing high-grade intersections that are enveloped by larger bulk tonnage style intersections. We anticipate more results from 2018 infill and step-out d

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom